Emmanuel C Patin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Emmanuel C Patin

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Nature Communications|July 8, 2025

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse modelsJoan Kyula-Currie, Victoria Roulstone, James Wright, et al.

Nature Communications|August 12, 2024

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapyEmmanuel C Patin, Pablo Nenclares, Charleen Chan Wah Hak, et al.

Nature Communications|May 24, 2025

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.

The Journal of Clinical Investigation|November 7, 2023

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.

Immunity|May 24, 2024

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell deathJonathan Mannion, Valentina Gifford, Benjamin Bellenie, et al.

Pageof 3

Search research articles

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Nature Communications|July 8, 2025

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse modelsJoan Kyula-Currie, Victoria Roulstone, James Wright, et al.

Nature Communications|August 12, 2024

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapyEmmanuel C Patin, Pablo Nenclares, Charleen Chan Wah Hak, et al.

Nature Communications|May 24, 2025

Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.

The Journal of Clinical Investigation|November 7, 2023

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.

Immunity|May 24, 2024

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell deathJonathan Mannion, Valentina Gifford, Benjamin Bellenie, et al.

Pageof 3